Biocartis names Dr. Nayan Gregory Parekh as CEO
Current ceo rudi pauwels becomes executive chairman focusing on scientific and technology strategy
Biocartis announced the appointment of Dr. Nayan Gregory Parekh as its new Chief Executive Officer.
Parekh brings to Biocartis a wealth of pharmaceutical and biotechnology industry experience and has been an Executive Director of the Company’s Board since April 2011. Rudi Pauwels, co-founder of Biocartis and current CEO, will become Executive Chairman and will dedicate his time to the Company’s scientific and technology strategy.
Biocartis is moving into a new strategic phase as it focuses on building commercial capabilities and expanding industry partnerships. Dr. Parekh has held senior management positions at Novartis and Deutsche Bank and has a broad network of relationships and experience across a number of healthcare fields and geographies. Most recently, he was at New Rhein Healthcare LLC, a healthcare investment firm where he was one of the founding partners. Before setting up New Rhein, Dr.Parekh spent six years as head of corporate development at Novartis AG, where he led the Novartis investments in Eye Care, Vaccines, Diagnostics, Generics, as well as certain emerging markets such as China, Saudi Arabia, Brazil and Russia. He was also a member of the Novartis Group Finance Committee. Prior to joining Novartis in 2004, he spent ten years in investment banking, primarily focusing on the pharmaceutical and biotechnology sectors. Greg holds a PhD. from Northwestern University and received a B.A. in Economics and Political Science from the University of Rochester.
Other news from the department people
